4
Changes in Ownership
Adaptive Biotechnologies Corp Filed Acc 0001209191-20-061326
Chief Business Development Off sold 6,770 shares at an average $48.87 ($330,856)
- Chief Business Development Off acquired 6,770 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Option exercise | +2,604 | $6.55 | $17,056 | 2,604 | D: show line 1 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Option exercise | +2,604 | $6.55 | $17,056 | 5,208 | D: show line 2 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Option exercise | +1,562 | $7.27 | $11,356 | 6,770 | D: show line 3 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Sale | −3,077 | $48.20 | $148,311 | 3,693 | D: show line 4 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Sale | −3,693 | $49.43 | $182,545 | 0 | D: show line 5 in the form |
| Open-market sales · 6,770 sh · avg $48.87 · $330,856 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Option exercise · Stock Option (Right to Buy) | −2,604 | 28,646 | D: show line 6 in the form | |||||
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Option exercise · Stock Option (Right to Buy) | −2,604 | 57,292 | D: show line 7 in the form | |||||
| BENZENO SHARON Chief Business Development Off | 2020-12-01 | Option exercise · Common Stock (Right to Buy) | −1,562 | 39,063 | D: show line 8 in the form |
Loading xslF345X03/doc4.xml…